Login
Moderna Inc logo

Moderna Inc

modernatx.com

Moderna Inc (NASDAQ: MRNA) is a biotechnology company that discovers, develops, manufactures, and commercializes mRNA-based medicines. Revenue comes from product sales, primarily its COVID-19 vaccines. Moderna operates in the respiratory vaccine market alongside established pharmaceutical competitors, with its commercial portfolio consisting of three approved products as of FY2025: Spikevax and mNEXSPIKE (COVID-19 vaccines) and mRESVIA (RSV vaccine). mNEXSPIKE launched commercially in Q3 2025 and became the company's leading product in the U.S. retail channel. Total FY2025 revenue was $1.9 billion, largely from COVID vaccine sales. Beyond commercial products, Moderna is advancing a pipeline across oncology, rare disease, and infectious disease, including intismeran autogene (mRNA-4157), an individualized neoantigen therapy in development with Merck. The company is headquartered in the United States and filed its 10-K on February 20, 2026 (accession 000168285226000033).

Products & Services

Spikevax (COVID-19 vaccine), mNEXSPIKE (COVID-19 vaccine, launched Q3 2025, leading U.S. retail channel product as of FY2025), mRESVIA (RSV vaccine), and a development pipeline including intismeran autogene (mRNA-4157) individualized neoantigen therapy in oncology (Phase 2b with Merck's pembrolizumab/KEYTRUDA), plus early-stage programs in flu, flu+COVID combination, norovirus, rare disease, and oncology.

Revenue Model

Transactional product sales of approved mRNA vaccines, primarily COVID-19 vaccines (Spikevax and mNEXSPIKE) and the RSV vaccine mRESVIA, generating $1.9 billion in total FY2025 revenue.

Customers & Markets

Respiratory vaccine market (COVID-19, RSV); retail pharmacy channel in the U.S.; oncology and rare disease patients as pipeline matures. Government and institutional purchasers implied by vaccine distribution context in the filing.

Geographic Exposure

Filing references geographic expansion as a growth driver and mentions a global team, but specific revenue by geography is not detailed in the provided excerpts. U.S. retail channel explicitly cited for mNEXSPIKE.

Financial Snapshot

Revenue
TTM
$2.225B
Gross Margin
TTM
1.22%
Net Income
TTM
-$3.194B
Current Assets
2026 Q1
Current Liabilities
2026 Q1
Current Ratio
2026 Q1
240.92%
Total Assets
2026 Q1
Total Liabilities
2026 Q1
Book Value
2026 Q1
$7.408B
Cash
2026 Q1
P/E
Last 4 Quarters
N/A
Free Cash Flow
TTM
-$1.603B

Stock Price

Loading...
Market Cap: $26.589 Billion

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support